Clinical Trials Browser

Phase 2 × Endometrial Cancer Recurrent × Crizotinib × Clear all

NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Phase 2 Terminated

Endometrial Cancer Recurrent